论文部分内容阅读
Background and aim Information describing efficacy and safety of infliximab for Crohns disease (CD) in China is limited.The objective of this study was to report response rates, relapse rates after infliximab-induced remission, and adverse events, and identify factors associated with relapse in a cohort of CD patients treated with infliximab in a Chinese center.